Description
Development of methodology for purification and pre-clinical testing of a therapeutic to prevent vascular leakage in Acute Respiratory Distress Syndrome.
Amendment chain · 5 entries
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header. For this agreement: $1,799,444 at start, $6,860,170 after amendment #4 (+$5,060,726).
- #02021-02-09$1,799,444
- #12021-08-30$1,799,444
- #22021-11-09$3,489,024+$1,689,580
- #32022-03-17$3,489,024
- #42022-12-09$6,860,170+$3,371,146
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2021-02-09(start date) | $1,799,444 | — | Development of methodology for purification and pre-clinical testing of a therapeutic to prevent vascular leak… |
| #1 amendment | 2021-08-30 | $1,799,444 | +$0 | Development of methodology for purification and pre-clinical testing of a therapeutic to prevent vascular leak… |
| #2 amendment | 2021-11-09 | $3,489,024 | +$1,689,580 | Development of methodology for purification and pre-clinical testing of a therapeutic to prevent vascular leak… |
| #3 amendment | 2022-03-17 | $3,489,024 | +$0 | Development of methodology for purification and pre-clinical testing of a therapeutic to prevent vascular leak… |
| #4 amendment | 2022-12-09 | $6,860,170 | +$3,371,146 | Development of methodology for purification and pre-clinical testing of a therapeutic to prevent vascular leak… |
Related records · 5
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other recipients funded under "Industrial Research Assistance Program – Contributions to Firms" by National Research Council Canada | Conseil national de recherches Canada (most recent first)
| Ref | Recipient | Fiscal year | Current value | FY |
|---|---|---|---|---|
| 172-2025-2026-Q2-1034675 | Mediphage Bioceuticals, Inc. | FY2027 | $63,380 | FY2027 |
| 172-2025-2026-Q3-1037522 | OBKIO INC. | FY2026 | $50,000 | FY2026 |
| 172-2025-2026-Q3-1037889 | SERVICES DE DEVELOPPEMENT PROFESSIONELS SDP INC | FY2026 | $25,000 | FY2026 |
| 172-2025-2026-Q2-1034040 | Griffith Foods Limited | FY2026 | $54,880 | FY2026 |
| 172-2025-2026-Q3-1037273 | Apollo Machine & Welding Ltd. | FY2026 | $230,000 | FY2026 |
Cite as: Glassbox record view · Federal grants & contributions · 172-2020-2021-Q4-967028 · retrieved 2026-11-13.